Description

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, VETERINARY USE, OR IN VIVO DIAGNOSTIC PURPOSES.

Product Overview: Thymosin Alpha-1 (Tα1)

Thymosin Alpha-1 (Tα1) is a synthetic 28-amino acid, N-terminally acetylated peptide derived from prothymosin alpha, mimicking the peptide naturally isolated from human thymic tissue. As an essential coordinator of innate and adaptive immune pathways, Tα1 functions as an immunomodulator that binds to pattern recognition receptors (such as TLR-2 and TLR-9) to promote T-cell precursor maturation, enhance natural killer cell activity, and restore cellular immune balance without triggering uncontrollable inflammatory cascades.

Primary Purpose: Research settings utilize Thymosin Alpha-1 primarily to restore, optimize, and balance compromised immune function—specifically by accelerating T-cell production and enhancing cellular defense mechanisms without overstimulating systemic inflammation.

Primary Research Applications & Reasons for Study

Lymphocyte Maturation: Reversing T-cell depletion and accelerating the differentiation of immature precursor cells into functional CD4+ (helper) and CD8+ (cytotoxic) T-lymphocytes.
Pathogen Defense Mechanisms: Enhancing Natural Killer (NK) cell cytotoxicity and dendritic cell antigen presentation against viral, bacterial, and fungal assay targets.
Cytokine Regulation: Balancing pro- and anti-inflammatory signaling networks to suppress hyper-inflammatory damage while maintaining robust immune defense.
Oncology & Adjunctive Protocols: Investigating improved tumor recognition and immune restoration during cytotoxic or chemotherapeutic exposure models.

Expected Research Results & Timeline Metrics

Phase 1 / Days 1–14
Initial Priming: Early cellular activation via Toll-Like Receptor (TLR-2/TLR-9) pathways and elevated upregulation of terminal deoxynucleotidyl transferase (TdT).
Phase 2 / Weeks 2–4
Cellular Expansion: Statistically significant increases in circulating mature CD4+/CD8+ T-cell populations, elevated NK cell clearance activity, and heightened antibody responses.
Phase 3 / Weeks 4–8
Cytokine Realignment: Normalization of serum cytokine ratios—marked by increased Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) alongside suppressed TNF-α and IL-1β expression.

Key Research Benefits

Targeted T-Cell Development: Drives rapid maturation and differentiation of T-lymphocytes in both thymic and peripheral tissue assays.
Dual Immunomodulatory Control: Upregulates sluggish immune responses while dampening hyper-inflammatory cytokine storms.
Broad-Spectrum Surveillance: Improves clearing kinetics and host recognition during persistent infection protocols.
Cellular Antioxidant Defense: Increases endogenous antioxidant enzymes (glutathione peroxidase) to protect immune cells from oxidative degradation.

Regulatory Compliance & Legal Research Disclaimer

THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research peptides.

Additional information

Size	5 mg